Subconjunctival Injection of Bevacizumab (Avastin) on Corneal Neovascularization in Different Rabbit Models of Corneal Angiogenesis

被引：69
作者：
Chen, Wei-Li [1 ,2 ]
Lin, Chung-Tien [3 ]
Lin, Nien-Ting [3 ]
Tu, I-Hua [1 ,2 ]
Li, Jing-Wen [1 ,2 ]
Chow, Lu-Ping [4 ]
Liu, Kwan-Rong [1 ]
Hu, Fung-Rong [1 ,2 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Ctr Corneal Tissue Engn & Stem Cell Biol, Taipei, Taiwan
[3] Natl Taiwan Univ, Dept Vet Med, Coll Bioresource & Agr, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Grad Inst Biochem & Mol Biol, Taipei 10764, Taiwan
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2009年 / 50卷 / 04期
关键词：
ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; FACTOR VEGF; MACULAR DEGENERATION; ALKALI BURN; EXPRESSION; INHIBITION; CELLS; TOXICITY; THERAPY;
D O I：
10.1167/iovs.08-1997
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
PURPOSE. Bevacizumab is a potent recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). The purpose of this study was to evaluate the therapeutic effect of subconjunctival injection of bevacizumab on corneal neovascularization (NV) in different rabbit models. METHODS. Several rabbit models of corneal NV were used, including (1) a corneal micropocket assay with VEGF pellet, (2) a corneal micropocket assay with basic fibroblast growth factor (b-FGF) pellets, (3) mechanical limbal injury-induced corneal NV, and (4) an alkali-induced model of corneal NV. Subconjunctival injections of bevacizumab (0.25-2.5 mg) were applied twice per week for 2 to 8 weeks. Digital photographs of the cornea were analyzed to determine the length of corneal NV and the area of cornea covered by NV as a percentage of the total corneal area. Immunohistochemical staining with antihuman IgG antibody labeled with Cy3 was used to determine the detection of intracorneal distribution of bevacizumab after injection. RESULTS. Subconjunctival injection of bevacizumab caused significant inhibition of corneal NV formation as measured by length or surface area in all animal models (P < 0.05). No significant ocular complications were found. Staining of bevacizumab was found in the corneal stroma for 3 to at least 14 days in the different rabbit models. CONCLUSIONS. Subconjunctival injection of bevacizumab is effective in inhibiting corneal NV in several rabbit models. Bevacizumab may diffuse into the corneal stroma and persist for a few days after injection. It may be useful in preventing corneal NV in the acute phase of various kinds of corneal inflammation. (Invest Ophthalmol Vis Sci. 2009; 50: 1659-1665) DOI:10.1167/iovs.08-1997
引用
收藏
页码：1659 / 1665
页数：7
相关论文
共 46 条
[1]   The role of vascular endothelial growth factor \in ocular health and disease [J].
Adamis, AP ;
Shima, DT .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2005, 25 (02) :111-118
[2]  
Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
[3]   Anti-vascular endothelial growth factor therapy for ocular neovascular disease [J].
Andreoli, Christopher M. ;
Miller, Joan W. .
CURRENT OPINION IN OPHTHALMOLOGY, 2007, 18 (06) :502-508
[4]   Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].
Avery, RL ;
Pieramici, DJ ;
Rabena, MD ;
Castellarin, AA ;
Nasir, MA ;
Giust, MJ .
OPHTHALMOLOGY, 2006, 113 (03) :363-372
[5]   Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium [J].
Bahar, Irit ;
Kaiserman, Igor ;
McAllum, Penny ;
Rootman, David ;
Slomovic, Allan .
CURRENT EYE RESEARCH, 2008, 33 (01) :23-28
[6]   Subconjunctival bevacizumab lnjection for corneal neovascularization [J].
Bahar, Irit ;
Kaiserman, Igor ;
McAllum, Penny ;
Rootman, David ;
Slomovic, Allan .
CORNEA, 2008, 27 (02) :142-147
[7]   Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model [J].
Bakri, Sophie J. ;
Cameron, J. Douglas ;
McCannel, Colin A. ;
Pulido, Jose S. ;
Marler, Ronald J. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) :162-164
[8]   The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea [J].
Barros, Luiz F. M. ;
Belfort, Rubens, Jr. .
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2007, 79 (03) :389-394
[9]   Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study [J].
Bashshur, Ziad F. ;
Haddad, Zeina A. ;
Schakal, Alexandre ;
Jaafar, Rola F. ;
Saab, Marc ;
Noureddin, Baha' N. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (02) :249-256
[10]   Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis [J].
Binétruy-Tournaire, R ;
Demangel, C ;
Malavaud, B ;
Vassy, R ;
Rouyre, S ;
Kraemer, M ;
Plouët, J ;
Derbin, C ;
Perret, G ;
Mazie, JC .
EMBO JOURNAL, 2000, 19 (07) :1525-1533
12345